Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4610 in Advanced Solid Tumors
NCT07231211Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-4610 in solid tumor (8 cohorts). Primary endpoints: Dose-Limiting Toxicity at 1 year, Maximum Tolerated Dose at 1 year and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
SHR-4610
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07231211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231211.